DOK2 Antibody

What is DOK2 and what cellular functions does it regulate?

DOK2 (Docking protein 2, also known as p56dok-2) is an adaptor or scaffolding protein that serves as a docking platform for the assembly of multimolecular signaling complexes. It belongs to the DOK family of proteins that function as negative regulators in various signaling pathways.

At the molecular level, DOK2:

• Contains a PH (Pleckstrin homology) domain that mediates lipid/protein interactions

• Acts as a negative regulator by recruiting Ras GTPase-activating proteins

• Inhibits the Ras-MAPK pathway by attenuating MAP kinase activation

• Modulates PI3K-Akt signaling through inhibition of Akt phosphorylation

DOK2 plays significant roles in multiple cellular contexts:

• Regulates CD8+ T cell signaling and memory formation

• Serves as a tumor suppressor gene

• Functions in platelet signaling through interaction with integrin αIIβ3

• Negatively regulates T-cell receptor signaling

• Modulates lipopolysaccharide-induced signaling in immune responses

What are the recommended applications for DOK2 antibodies in research protocols?

Based on current literature and commercial products, DOK2 antibodies can be utilized in several experimental applications:

Positive controls:

• Jurkat cells consistently show DOK2 expression and are recommended for validation

• Human lymphoma tissue has been verified for IHC applications

For phospho-specific DOK2 antibodies, stimulation of cells with appropriate ligands (e.g., EGF) is necessary to induce phosphorylation before detection .

How should researchers validate DOK2 antibodies before experimental use?

A multi-step validation approach is essential:

• Western blot verification:

  • Confirm band at expected molecular weight (45-56 kDa)

  • Include positive controls (Jurkat cells)

  • For phospho-antibodies, compare stimulated vs. unstimulated samples

• Specificity controls:

  • Use blocking peptides where available (e.g., catalog no. 33R-7536 mentioned for certain antibodies)

  • Include knockout/knockdown samples as negative controls

  • For phospho-specific antibodies, treat with phosphatase to confirm specificity

• Cross-reactivity assessment:

  • Test on known positive and negative species samples based on sequence homology

  • Verify reactivity with human, mouse, and rat samples as appropriate

• Application-specific validation:

  • For IHC, optimize antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • For IF applications, compare different fixation methods

How does DOK2 regulate T cell memory formation and what experimental approaches are optimal for investigating this phenomenon?

DOK2 plays a significant role in regulating CD8+ T cell memory formation through several mechanisms:

Key mechanisms and experimental findings:

• DOK1 and DOK2 depletion in CD8+ T cells induces a higher percentage of effector memory T cells

• Pre-stimulated DOK1/DOK2 double knockout (DKO) CD8+ T cells show enhanced TCR signaling with increased phosphorylation of AKT and ERK

• This improved signaling is not observed in naïve CD8+ T cells, suggesting context-dependent regulation

• Despite enhanced TCR signaling, DOK1/DOK2 DKO CD8+ T cells do not show increased cytotoxic capacity against tumor cells in vitro

Recommended experimental approaches:

• T cell memory phenotyping:

  • Flow cytometry analysis of memory markers (CD44, CD62L, CD127) in WT vs. DOK2 KO cells

  • Time-course analysis of memory development following antigen challenge

• Signaling pathway analysis:

  • Phospho-flow cytometry to measure pAKT and pERK levels after TCR stimulation

  • Compare signaling in naïve versus pre-stimulated CD8+ T cells

  • Use anti-CD3 mAbs at different concentrations to assess signaling threshold differences

• In vivo memory models:

  • Adoptive transfer of WT vs. DOK2 KO T cells, followed by infection/vaccination

  • Assessment of memory response magnitude and quality upon rechallenge

  • Analysis of memory precursor populations early after stimulation

• Functional assays:

  • Cytokine production measurement by intracellular staining and ELISA

  • Proliferation assays using CFSE or similar dyes

  • Cytotoxicity assays against target cells to distinguish memory effects from killing capacity

What approaches should be used when studying DOK2 phosphorylation dynamics in immune cell activation?

DOK2 phosphorylation is a dynamic process that requires precise experimental design:

Phosphorylation sites and their significance:

• Tyr299: Important for downstream signaling

• Tyr351: Critical for recruitment of binding partners

• Multiple other tyrosine residues contribute to DOK2 function

Experimental protocol recommendations:

How can researchers effectively distinguish between DOK family members when studying their roles in immune regulation?

The DOK family consists of multiple members with structural similarities but distinct functions. Distinguishing between them requires careful experimental design:

Structural and functional differences:

• DOK1 and DOK2 are the most extensively studied and share significant homology

• Both contain PH domains, phosphotyrosine-binding (PTB) domains, and C-terminal regions with multiple tyrosines

• They often function cooperatively but may have distinct binding partners and functions

Strategic approaches for differentiation:

• Antibody selection criteria:

  • Choose antibodies targeting unique epitopes not conserved between DOK family members

  • Validate specificity using overexpression systems with individual DOK proteins

  • Consider using C-terminal targeting antibodies where sequence divergence is greater

• Genetic manipulation approaches:

  • Use single knockout models to assess individual contributions

  • Compare with double knockout models to identify redundancy or synergy

  • Implement selective knockdowns with siRNA/shRNA targeting unique regions

  • Consider rescue experiments with individual DOK members

• Expression pattern analysis:

  • Compare tissue and cell-type specific expression of DOK family members

  • Utilize single-cell RNA sequencing to identify differential expression

  • Examine developmental regulation of different DOK proteins

• Interaction partner identification:

  • Perform co-immunoprecipitation with DOK-specific antibodies

  • Use mass spectrometry to identify unique binding partners

  • Apply proximity labeling approaches (BioID, APEX) to map protein interactions in intact cells

• Phosphorylation site-specific analysis:

  • Target antibodies to unique phosphorylation sites

  • Perform phospho-proteomics to identify differentially regulated sites

  • Create phosphorylation site mutants to distinguish functional roles

What are the optimal conditions for detecting DOK2 in specific cell types and tissues of interest?

Detection of DOK2 varies across cell types and requires optimization:

Cell and tissue expression patterns:

• Highly expressed in hematopoietic cells (T cells, NK cells, macrophages)

• Present in Jurkat cells (human T lymphocyte line)

• Detected in human lymphoma tissue

• Expression in non-immune tissues is generally lower

Optimization recommendations by technique:

• Western blotting optimization:

  • Lysate preparation: Use RIPA buffer with protease and phosphatase inhibitors

  • Protein loading: 20-50 μg total protein recommended

  • Antibody dilutions: 1:500-1:2400 depending on antibody sensitivity

  • Detection system: Enhanced chemiluminescence (ECL) systems work well

  • Expected band: 56 kDa observed molecular weight

• Immunohistochemistry considerations:

  • Fixation: 10% neutral buffered formalin is standard

  • Antigen retrieval: TE buffer pH 9.0 is recommended; citrate buffer pH 6.0 is an alternative

  • Antibody dilution: 1:20-1:200 range, requiring optimization

  • Counterstain: Hematoxylin works well for contrast

  • Positive control: Human lymphoma tissue

• Immunofluorescence protocol:

  • Fixation: Methanol fixation has been validated for some antibodies

  • Permeabilization: 0.1% Triton X-100 if needed after formaldehyde fixation

  • Blocking: 5% normal serum from secondary antibody species

  • Antibody dilution: 1:100-1:200 range

  • Nuclear counterstain: DAPI is recommended

• Flow cytometry considerations:

  • For intracellular staining: Fixation with 4% paraformaldehyde followed by permeabilization

  • For phospho-flow: Fix with 1.5% formaldehyde, permeabilize with methanol

  • Antibody concentration: Requires titration for optimal signal-to-noise ratio

  • Controls: Include isotype controls and positive controls (e.g., stimulated samples for phospho-DOK2)

How do DOK1 and DOK2 cooperatively regulate NK cell development and function?

DOK1 and DOK2 play critical roles in NK cell biology with significant implications for immunology research:

Key regulatory functions:

• Both DOK1 and DOK2 are expressed in primary NK cells and NK cell lines

• They undergo tyrosine phosphorylation upon triggering of activating receptors (NKp30, NKG2D, 2B4)

• Act as negative regulators of NK cell cytotoxicity and function

• Affect NK cell development and maturation in the bone marrow and peripheral tissues

Experimental findings on NK cell development:

• DOK1/DOK2 double knockout (DKO) mice show reduced numbers of peripheral NK cells

• DKO mice display an accumulation of immature CD27highCD11blow NK cells

• A block in NK cell transition from CD27highCD11bhighKLRG-1low to CD27lowCD11bhighKLRG-1high stages is observed

• Similar effects on terminal differentiation markers like CD43 are observed

Methods for studying DOK effects on NK cell function:

• Cytotoxicity assays:

  • 51Cr release assays comparing NK cells from wild-type vs. DKO mice

  • Target cells: Various tumor cell lines (K562, YAC-1)

  • Analysis of dose-response relationships at different effector:target ratios

  • Compare overexpression of full-length DOK proteins vs. ΔPH-Dok mutants

• Signaling pathway analysis:

  • Phosphorylation of AKT and ERK-1/2 following NKp46 engagement

  • Comparison of low-dose vs. saturating doses of activating antibodies

  • Phosphoflow cytometry allows single-cell resolution of signaling events

  • Western blot analysis of immunoprecipitated signaling complexes

• Cytokine production assessment:

  • IFN-γ production upon receptor triggering (NKp46, Ly49D)

  • Response to cytokine stimulation (IL-12, IL-18)

  • Comparison of cytokine production after poly(I:C) priming

  • Intracellular cytokine staining combined with maturation markers

• Development and maturation analysis:

  • Flow cytometry panels examining NK developmental stages

  • Markers: CD27, CD11b, KLRG-1, CD43

  • Analysis across multiple tissues (bone marrow, spleen, lymph nodes)

  • Heterozygous mice can reveal gene dosage effects

What are common pitfalls when using DOK2 antibodies and how can they be addressed?

Researchers frequently encounter challenges when working with DOK2 antibodies:

Common issues and solutions:

• Non-specific bands in Western blots:

  • Problem: Additional bands beyond the expected 45-56 kDa

  • Solutions:

    • Increase antibody dilution (1:1000-1:2400)

    • Use blocking peptides for competitive inhibition

    • Optimize blocking conditions (5% BSA often better than milk for phospho-antibodies)

    • Include positive controls (Jurkat cells) and negative controls

• Weak or no signal in immunohistochemistry:

  • Problem: Poor or absent staining despite DOK2 expression

  • Solutions:

    • Test different antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

    • Optimize antibody concentration (try 1:20 dilution for weak antibodies)

    • Extend primary antibody incubation time (overnight at 4°C)

    • Use amplification systems like tyramide signal amplification

• Phosphorylation detection challenges:

  • Problem: Inconsistent phospho-DOK2 detection

  • Solutions:

    • Ensure rapid sample processing with phosphatase inhibitors

    • Optimize stimulation conditions (timing, concentration)

    • Use fresh samples; avoid freeze-thaw cycles

    • For phospho-flow, fix samples immediately after stimulation

• Cross-reactivity with other DOK family members:

  • Problem: Antibody recognizes multiple DOK proteins

  • Solutions:

    • Select antibodies raised against unique epitopes

    • Validate with overexpression systems

    • Use knockout/knockdown samples as controls

    • Consider C-terminal targeting antibodies where sequence divergence is higher

• Validation table for troubleshooting strategies:

  Issue	Validation Approach	Expected Outcome
  Specificity concerns	Western blot with blocking peptide	Disappearance of specific band
  Multiple bands	Gradient gel with varied protein loading	Better band separation
  Weak phospho-signal	Optimize stimulation time course	Identification of peak phosphorylation
  Inconsistent results	Standardize cell lysis protocol	Improved reproducibility
  Background in IHC/IF	Test multiple blocking reagents	Reduced non-specific binding

How should researchers interpret conflicting results when studying DOK2 function across different experimental systems?

DOK2 functions can appear contradictory across different experimental contexts, requiring careful interpretation:

Sources of experimental variability:

• Cell type-specific effects:

  • DOK2 functions differently in T cells vs. NK cells vs. macrophages

  • Naïve CD8+ T cells vs. pre-stimulated cells show different DOK2 dependencies

  • Expression levels vary across cell types affecting functional outcomes

• Receptor context influences:

  • DOK2 regulates various receptors differently (TCR, cytokine receptors, TLRs)

  • In CD8+ T cells, DOK2 inhibits TCR signaling but not tumor cell killing

  • In NK cells, DOK2 inhibits activating receptor signaling but can enhance cytokine receptor responses

• Genetic model considerations:

  • Single vs. double knockout models reveal redundancy

  • Complete knockout vs. conditional knockout timing affects interpretation

  • Compensatory mechanisms may develop in constitutive knockout models

Reconciliation strategies:

What are the critical experimental controls needed when using phospho-specific DOK2 antibodies?

Phospho-specific antibodies require rigorous validation and controls:

Essential control experiments:

• Stimulation controls:

  • Unstimulated samples (negative control)

  • Positive stimulation with known activators:

    • Anti-CD3 antibodies for T cells

    • NKp30, NKG2D, or 2B4 antibodies for NK cells

    • EGF for cells expressing EGFR

  • Time-course experiments to capture transient phosphorylation

• Specificity validation controls:

  • Phosphatase treatment of lysates (should eliminate signal)

  • Competitive inhibition with phospho-peptide

  • Mutation of the target phosphorylation site (Y299A, Y351A)

  • Use of DOK2 knockout or knockdown cells

• Cross-reactivity assessment:

  • Test for reactivity with unphosphorylated DOK2

  • Check for recognition of other phosphorylated DOK family members

  • Validate with overexpression systems (wild-type vs. phospho-mutants)

• Technical validation controls:

  • Total DOK2 antibody blotting in parallel with phospho-antibody

  • Loading controls (β-actin, GAPDH, or total protein stain)

  • Phosphorylation of known proteins in the same pathway (pERK, pAKT)

  • Isotype control antibodies for flow cytometry and immunofluorescence

• Validation data example:

  Control Type	Experimental Design	Expected Result
  Stimulation validation	Western blot of unstimulated vs. stimulated samples	Signal in stimulated lane only
  Phosphatase control	Treat half of stimulated lysate with lambda phosphatase	Signal loss in treated sample
  Specificity confirmation	Pre-incubate antibody with phospho-peptide vs. non-phospho-peptide	Signal blocked only by phospho-peptide
  Downstream validation	Blot for pERK after stimulation with/without DOK2 inhibition	Enhanced pERK when DOK2 is inhibited
  siRNA validation	Compare phospho-signal in control vs. DOK2 siRNA-treated cells	Signal reduction in knockdown cells

How might DOK2 antibodies be utilized to develop novel cancer immunotherapy approaches?

Current research suggests potential for DOK2-focused immunotherapeutic strategies:

DOK2 in cancer biology:

• Functions as a tumor suppressor gene

• Located on human chromosome 8p21.3, a region frequently deleted in cancers

• Negatively regulates EGFR, PDGFR, and Her-2/NEU-8 signaling via feedback modulation

• Inhibits Ras-MAPK and Akt pathways relevant to cancer progression

Potential therapeutic applications:

• Enhanced T cell memory formation:

  • DOK1/DOK2 depletion increases effector memory T cell percentages

  • Pre-stimulated DOK-depleted CD8+ T cells show enhanced TCR signaling

  • Despite not directly enhancing tumor cell killing, memory enhancement could improve long-term anti-tumor immunity

  • Approach: Transient inhibition of DOK2 during T cell priming for adoptive cell therapy

• NK cell-based immunotherapy optimization:

  • DOK proteins negatively regulate NK cell development and function

  • Targeting DOK2 could enhance NK responsiveness to activating receptors

  • Improved IFN-γ production with DOK2 inhibition could enhance anti-tumor responses

  • Challenge: Context-dependent effects require careful targeting strategy

• Biomarker development:

  • DOK2 expression or phosphorylation status as a predictive biomarker

  • Assessment of DOK2 levels in tumor-infiltrating lymphocytes

  • Correlation of DOK2 status with immunotherapy response

  • Methodological approach: Multiplex IHC combining DOK2 with immune cell markers

• Experimental design considerations:

  Approach	Methodology	Research Questions	Technical Requirements
  T cell engineering	CRISPR/siRNA DOK2 targeting	Durability of memory enhancement	DOK2 antibodies for validation
  Small molecule inhibition	Structure-based drug design	Specificity vs. other DOK proteins	Phospho-specific antibodies to monitor target engagement
  Timing optimization	Transient vs. stable DOK2 inhibition	Effect on different phases of immune response	Antibodies for monitoring expression kinetics
  Combination therapy	DOK2 inhibition + checkpoint blockade	Synergistic potential	Multi-parameter analysis with DOK2 and checkpoint markers

What emerging technologies could enhance the study of DOK2 in immune cell signaling networks?

Cutting-edge approaches are transforming DOK2 research:

Advanced methodologies:

• Phospho-proteomics integration:

  • Mass spectrometry-based analysis of DOK2 phosphorylation sites

  • Identification of novel phosphorylation sites beyond Y299, Y351

  • Network analysis of DOK2-dependent phosphorylation events

  • Temporal dynamics of phosphorylation changes

  • Requirement: Validation of mass spec findings with site-specific antibodies

• Single-cell technologies:

  • Single-cell RNA-seq to identify DOK2 expression heterogeneity

  • CyTOF (mass cytometry) with DOK2 and phospho-DOK2 antibodies

  • Single-cell phospho-flow cytometry for population-level signaling analysis

  • Spatial transcriptomics to map DOK2 expression in tissue contexts

  • Application: Heterogeneity of DOK2 function across immune cell subsets

• Advanced imaging approaches:

  • Super-resolution microscopy to visualize DOK2 signaling complexes

  • Live-cell imaging with fluorescent DOK2 fusion proteins

  • FRET/BRET systems to monitor DOK2 interactions in real-time

  • Optogenetic control of DOK2 function or localization

  • Integration: Combine with DOK2 antibodies for validation

• Systems biology integration:

  • Computational modeling of DOK2 signaling networks

  • Machine learning approaches to predict DOK2 function in different contexts

  • Multi-omics integration (transcriptomics, proteomics, phospho-proteomics)

  • Pathway analysis tools incorporating DOK2 signaling nodes

  • Requirement: High-quality antibody-based datasets as training inputs

• Technology implementation table:

  Technology	Application to DOK2 Research	Antibody Requirements
  CyTOF	Simultaneous analysis of DOK2 with dozens of markers	Metal-conjugated DOK2 antibodies
  Imaging mass cytometry	Spatial mapping of DOK2 in tissue sections	Validation of antibody specificity in multiplex systems
  CRISPR screens	Identification of genes modulating DOK2 function	Antibodies for phenotypic readouts
  Proximity proteomics (BioID/APEX)	Mapping DOK2 interaction partners	Antibodies to validate proteomic hits
  Organoid systems	DOK2 function in 3D tissue-like environments	Optimized antibodies for 3D imaging

How does the study of DOK2 contribute to our understanding of immune dysregulation in disease?

DOK2 research provides insights into immune pathologies:

Disease relevance of DOK2:

• Cancer immunobiology:

  • DOK2 acts as a tumor suppressor gene

  • Loss of DOK2 may contribute to oncogenesis through enhanced RTK signaling

  • DOK2 expression in tumor-infiltrating lymphocytes could affect anti-tumor responses

  • Research directions: Correlation of DOK2 status with immunotherapy outcomes

• Inflammatory disorders:

  • DOK2 negatively regulates LPS-induced signaling

  • DOK1/DOK2 deficiency leads to hypersensitivity to endotoxin

  • Inhibition of TNF-α and nitric oxide production is mediated by DOK proteins

  • Implication: DOK2 dysfunction could contribute to inflammatory pathologies

• Neurodegenerative conditions:

  • DOK2 interacts with CD200R in microglia

  • CD200R-DOK2 axis regulates microglial activation

  • Potential relevance to neuroinflammatory processes

  • Research application: Study of DOK2 in models of neurodegeneration

• Viral infections:

  • DOK1/DOK2 proteins affect CD8+ T-cell response to vaccinia viral infection

  • These proteins regulate TCR expression after viral antigen stimulation

  • DOK proteins prevent overactivation of CD8+ T-cells and promote memory formation

  • Some viruses mimic CD200 to evade immunity via the CD200R-DOK2 axis

• Experimental models for disease studies:

  Disease Context	Experimental Approach	Antibody Applications
  Cancer	Analysis of tumor samples for DOK2 expression/deletion	IHC with validated antibodies in tissue microarrays
  Inflammatory disorders	DOK2 KO mouse response to inflammatory stimuli	Phospho-specific antibodies to track activation state
  Viral infections	T cell response kinetics with DOK2 manipulation	Multi-parameter flow cytometry with DOK2 antibodies
  Neurodegeneration	Microglial DOK2 expression in disease models	Dual IHC for DOK2 and microglial markers
  Autoimmunity	DOK2 polymorphisms and expression in patient samples	Genotype-phenotype correlation with expression analysis